Paul Ford

The Long-Term Athlete Development model: Physiological evidence and application

Paul Ford, Mark De Ste Croix, Rhodri S. Lloyd et al. · Journal of Sports Sciences · 2011 · 478 citations

Education, Human Development, Physiology +10

Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

Rudolf A. de Boer, Gilles W. De Keulenaer, Johann Bauersachs et al. · European Journal of Heart Failure · 2019 · 294 citations · Full text

Medicine, Cardiology, Pathology +16

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 235 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis

Nikhil Hirani, Alison C. MacKinnon, Lisa Nicol et al. · European Respiratory Journal · 2020 · 219 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade

Lynda Vuong, Eleni Kouverianou, Claire Rooney et al. · Cancer Research · 2019 · 141 citations · Full text

Medicine, Immunology, Oncology +16